Jean Gariépy Research Laboratory has been working for many years on the design of peptide-based delivery vehicles.1-13
Drug delivery often remains the key step in turning new drugs (small
molecules, peptides, proteins or DNA) into useful medicines. Delivery
systems commonly used in the pharmaceutical industry can be grouped
into either physical approaches (needles, gene gun, etc.) or chemical
formulations (liposomes, polymer/nanoparticles and more recently
cell-penetrating peptides). Viral vectors, although attractive as a
strategy for gene delivery, present major challenges (immune response,
large-scale production, toxicity) that can be more effectively answered
with future advances in chemical, non-viral formulations.14
Currently some of the most interesting new vehicles for delivering drug
cargos are cationic polymers. Cationic lipids and polymers (such as
polyethylenimine, PEI) enter cells efficiently and are widely used as
transfection agents in delivering plasmids and oligonucleotides into
eukaryotic cells.15,16
These agents titrate the negative charges on nucleic acids resulting in
condensed, cationic complexes that are readily internalized by cells.
Short cationic peptides can also act as protein transduction domains
(PTDs, also termed cell-penetrating peptides, or CPPs) and shuttle
drugs, peptides, proteins, oligonucleotides as well as large
macromolecules (up to several hundreds of nanometers in size) into
cells.17-19 PTDs can also be introduced directly into
recombinant proteins or synthetic peptides, generating biomolecular
conjugates with a built-in ability to be internalized by cells.
Typically, PTDs are sequences rich in lysine or arginine (Rn, where n
≥ 8) residues, with some sequences originally derived from basic
domains of proteins, such as the Tat peptide from the HIV-1 Tat
transcriptional transactivator and the Antennapedia homeodomain.20-29
Our laboratory has recently established the importance of multivalency
in the endocytosis of PTDs into eukaryotic cells: when presented on a
defined scaffold as a multivalent ligand, the overall affinity, or avidity, for its receptor is greatly enhanced over the affinity of a monovalent counterpart.1,2
Our laboratory has demonstrated that peptide dendrimers act as
efficient delivery vehicles for drugs, biogenic peptides and nucleic
acids in vitro3,5-7 and in vivo.4
A rich source of peptide dendrimers can be found in the quaternary
structure of natural proteins, and peptides derived from their
oligomerization domains represent excellent candidates for engineering
multivalent scaffolds. With a targeting ligand, such as a peptide
hormone analogue, incorporated directly in the primary sequence, these
oligomeric peptides self-assemble in a Lego-like fashion into compact,
defined multivalent ligands.8 We have used, for example, the
30-residue tetramerization domain of the human p53 tumour suppressor,
p53tet, as a scaffold to construct highly avid, tetravalent PTDs. These
constructs exhibit greatly enhanced cell entry by receptor-mediated
endocytosis relative to monovalent PTDs (Figure 1 = movie).1,2
An important design aspect with respect to noncovalently linked
oligomers is the stability of their quaternary structure. Specifically,
these oligomeric scaffolds must remain stable at low concentrations. To
this end, we have developed and characterized a tandem-dimerized
variant of the p53tet domain (Figure 2). This construct, termed
p53tetTD, retains a dimeric structure at concentrations at which
wildtype p53tet is monomeric (Figure 3).9 This is an example of a highly stabilized oligomeric scaffold that would resist dissociation at dilute concentrations.